IMNM
Price
$16.47
Change
-$0.93 (-5.34%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
2.46B
31 days until earnings call
Intraday BUY SELL Signals
KROS
Price
$10.68
Change
-$0.42 (-3.78%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
223.65M
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMNM vs KROS

IMNM vs KROS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMNM vs. KROS commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Hold and KROS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMNM with price predictions
Oct 15, 2026

IMNM in -10.18% downward trend, declining for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IMNM declined for three days, in 261 of 303 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

IMNM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IMNM crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

The Aroon Indicator for IMNM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 238 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

IMNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.690) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for KROS with price predictions
Oct 15, 2026

Momentum Indicator for KROS turns negative, indicating new downward trend

KROS saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 75 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 32 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

KROS moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

KROS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 229 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 191 of 230 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (26.782). P/E Ratio (4.778) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMNM vs KROS: Fundamental Ratings
IMNM
KROS
OUTLOOK RATING
1..100
7819
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
6557
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5044

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KROS's Valuation (51) in the null industry is in the same range as IMNM (65). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.

KROS's Profit vs Risk Rating (100) in the null industry is in the same range as IMNM (100). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.

KROS's SMR Rating (95) in the null industry is in the same range as IMNM (98). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.

KROS's Price Growth Rating (57) in the null industry is in the same range as IMNM (65). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.

KROS's P/E Growth Rating (100) in the null industry is in the same range as IMNM (100). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNMKROS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (IMNM: $17.40 vs. KROS: $11.10)
Brand notoriety: IMNM and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNM: 117% vs. KROS: 41%
Market capitalization -- IMNM: $2.46B vs. KROS: $223.65M
IMNM [@Biotechnology] is valued at $2.46B. KROS’s [@Biotechnology] market capitalization is $223.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNM’s FA Score shows that 0 FA rating(s) are green while KROS’s FA Score has 0 green FA rating(s).

  • IMNM’s FA Score: 0 green, 5 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMNM and KROS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNM’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 3 bullish TA indicator(s).

  • IMNM’s TA Score: 4 bullish, 4 bearish.
  • KROS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, IMNM is a better buy in the short-term than KROS.

Price Growth

IMNM (@Biotechnology) experienced а -9.89% price change this week, while KROS (@Biotechnology) price change was -4.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.70%. For the same industry, the average monthly price growth was -18.24%, and the average quarterly price growth was -21.46%.

Reported Earning Dates

IMNM is expected to report earnings on Nov 16, 2026.

KROS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-10.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMNM
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SLVX12.710.57
+4.70%
Nicholas Silver Income ETF (SLVX)
GMOD27.640.18
+0.65%
GMO Dynamic Allocation ETF (GMOD)
CMF54.790.34
+0.62%
iShares California Muni Bond ETF (CMF)
DABS49.710.10
+0.20%
Doubleline Asset-Backed Securities ETF
CHW7.94N/A
N/A
Calamos Global Dynamic Income Fund

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.45%
AXON - KROS
43%
Loosely correlated
+2.15%
ABEO - KROS
43%
Loosely correlated
+6.65%
EYPT - KROS
43%
Loosely correlated
+4.32%
IMNM - KROS
42%
Loosely correlated
+1.16%
SANA - KROS
42%
Loosely correlated
+6.22%
More